SBIR/STTR Research Award
Immuno-CometChip for Human Skin Basal Cell Genotoxicity Testing
Award amount
$152,999Program and phase
STTR · Phase IAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- TREVIGEN, INC.
- Proposal award date
- 2016-06-01
- Contract end date
- 2017-05-31
- UEI
- Not reported
- Solicitation number
- PA15-270
- Topic code
- 113
Research abstract
DESCRIPTION provided by applicant The objective of this Phase STTR research is to quantify genotoxicity in basal cell keratinocytes from organotypic cultures Epiderm in response to commonly used chemical agents The proposed product is a Comet Chip assay that measures DNA damage in basal cells derived from a reconstructed human epidermis Technical questions that will be addressed are Can we modify our currently used Comet Chip assay to incorporate extracellular matrix proteins or antibodies Can we isolate individual basal keratinocytes from a D organotypic skin culture on the basis of their preferential adhesion to these matrix proteins including collagen I and IV or by using immobilized antibodies to integrin Can we confirm their identity by quantum dot coupled antibodies specific for or collagen ligand integrins Can we use the isolated antibody labeled epidermal basal cells to detect and quantify levels of DNA damage in response to known environmental genotoxic agents Can we use our Immuno CometChip assay to screen large numbers of agents currently or proposed to be marketed The impact of the proposed research will be to reduce animal model use for toxic agent screening since human organotypic culture has been shown to be almost identical to human skin with respect to its cytokine profile in response to corrosive or irritating agents The market for screening skin genotoxic agents is immense since the current screening procedures cannot keep pace with the number of new agents currently being introduced Aim will be to develop a new method for the isolation of basal keratinocytes and an immunostaining method for simultaneous visualization of specific antigens including integrin and DNA damage Aim will be to validate the Immuno CometChip assay using known DNA damaging agents including H O This adds three new parameters to the Comet assay The first is obtaining treatment groups of single basal epidermal keratinocytes from an organotypic culture on a single chip the second is verifying their identity with surface markers and the third is the simultaneous reproducible assay for DNA damage
PUBLIC HEALTH RELEVANCE The Comet assay has appeal for many reasons The assay is rapid simple sensitive reliable and fairly inexpensive Its use for testing for skin toxicity hs been hampered by a number of factors including background DNA damage incurred during the normal process of differentiation in organotypic skin models which mimic human skin We therefore propose to develop a Comet Chip assay a high throughput reproducible and quantitative method to isolate basal keratinocytes and measure genotoxicity in response to commonly used chemical agents
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Development of an integrated smartphone-nanosensor platform for onsite biomonitoring of exposure to pesticides
- Novel sorbents for removal of PFAS from water
- A Personalized Digital Intervention Program to Reduce Exposure to Endocrine Disrupting Chemicals among a Child-Bearing Age Cohort
- Development and Evaluation of Rosette Array Technology for HumanNeurodevelopmental Toxicity Screening
- Wearable Multi-Gas Technologies for Monitoring Personal Air Quality